XFOR - B. Riley cuts X4 to neutral cites longer-term mavorixafor data
2023-12-12 15:25:46 ET
More on X4 Pharmaceuticals
- X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript
- X4 Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
- X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares
- X4 shares jump as FDA accepts priority review of pediatric WHIM drug
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
For further details see:
B. Riley cuts X4 to neutral, cites longer-term mavorixafor data